Cargando…

Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies

The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous interchange between cerebrospinal fluid and brain interstitial fluid by convective flow move...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohaupt, Pablo, Vialaret, Jérôme, Hirtz, Christophe, Lehmann, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566184/
https://www.ncbi.nlm.nih.gov/pubmed/37821965
http://dx.doi.org/10.1186/s13195-023-01318-2
_version_ 1785118869123235840
author Mohaupt, Pablo
Vialaret, Jérôme
Hirtz, Christophe
Lehmann, Sylvain
author_facet Mohaupt, Pablo
Vialaret, Jérôme
Hirtz, Christophe
Lehmann, Sylvain
author_sort Mohaupt, Pablo
collection PubMed
description The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous interchange between cerebrospinal fluid and brain interstitial fluid by convective flow movement. This flow is responsible for guiding proteins and metabolites away from the CNS. Proteinopathies are neurological conditions characterized by the accumulation of aggregated proteins or peptides in the brain. In Alzheimer’s disease (AD), the deposition of amyloid-β (Aβ) peptides causes the formation of senile plaques. This accumulation has been hypothesized to be a result of the imbalance between Aβ production and clearance. Recent studies have shown that an extended form of AQP4 increases Aβ clearance from the brain. In this mini-review, we present a summary of these findings and explore the potential for future therapeutic strategies aiming to boost waste clearance in AD.
format Online
Article
Text
id pubmed-10566184
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105661842023-10-12 Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies Mohaupt, Pablo Vialaret, Jérôme Hirtz, Christophe Lehmann, Sylvain Alzheimers Res Ther Mini Review The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous interchange between cerebrospinal fluid and brain interstitial fluid by convective flow movement. This flow is responsible for guiding proteins and metabolites away from the CNS. Proteinopathies are neurological conditions characterized by the accumulation of aggregated proteins or peptides in the brain. In Alzheimer’s disease (AD), the deposition of amyloid-β (Aβ) peptides causes the formation of senile plaques. This accumulation has been hypothesized to be a result of the imbalance between Aβ production and clearance. Recent studies have shown that an extended form of AQP4 increases Aβ clearance from the brain. In this mini-review, we present a summary of these findings and explore the potential for future therapeutic strategies aiming to boost waste clearance in AD. BioMed Central 2023-10-11 /pmc/articles/PMC10566184/ /pubmed/37821965 http://dx.doi.org/10.1186/s13195-023-01318-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Mini Review
Mohaupt, Pablo
Vialaret, Jérôme
Hirtz, Christophe
Lehmann, Sylvain
Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
title Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
title_full Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
title_fullStr Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
title_full_unstemmed Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
title_short Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
title_sort readthrough isoform of aquaporin-4 (aqp4) as a therapeutic target for alzheimer’s disease and other proteinopathies
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566184/
https://www.ncbi.nlm.nih.gov/pubmed/37821965
http://dx.doi.org/10.1186/s13195-023-01318-2
work_keys_str_mv AT mohauptpablo readthroughisoformofaquaporin4aqp4asatherapeutictargetforalzheimersdiseaseandotherproteinopathies
AT vialaretjerome readthroughisoformofaquaporin4aqp4asatherapeutictargetforalzheimersdiseaseandotherproteinopathies
AT hirtzchristophe readthroughisoformofaquaporin4aqp4asatherapeutictargetforalzheimersdiseaseandotherproteinopathies
AT lehmannsylvain readthroughisoformofaquaporin4aqp4asatherapeutictargetforalzheimersdiseaseandotherproteinopathies